All Life Sciences & Technology News
Top stories summarized by our editors
3/27/2017

A $130 billion merger between DuPont and Dow Chemical received conditional European Union antitrust approval today. DuPont agreed to sell assets including portions of its global pesticides business and Dow agreed to sell manufacturing plants in the US and Spain to secure the approval.

Full Story:
Reuters
More Summaries:
DuPont, Dow, EU
3/27/2017

ResTORbio, a subsidiary of PureTech Health, has gained exclusive rights to develop Novartis' two midstage mTORC1 inhibitors for aging-related indications. Under the agreement, Novartis will gain an equity stake in resTORbio and is eligible for milestone payments and royalties on sales.

More Summaries:
Novartis, PureTech Health, resTORbio
3/27/2017

The FDA has approved Shionogi and Purdue Pharma's Symproic, or naldemedine, as a treatment for adult patients with opioid-induced constipation who have chronic noncancer pain. Symproic is expected to launch this summer in 0.2-mg-strength tablets.

Full Story:
eMPR.com
More Summaries:
FDA, Purdue, Symproic, Shionogi
3/27/2017

A follow-on offering has raised $60 million for Bellicum Pharmaceuticals. The company is developing BPX-501, an adjunct T-cell drug for improving post-hematopoietic stem cell transplant outcomes.

Full Story:
BioCentury
3/27/2017

Genentech's Rituxan, or rituximab, received a breakthrough therapy designation from the FDA for the treatment of the rare and life-threatening autoimmune disorder pemphigus vulgaris. An ongoing late-stage study is evaluating Rituxan's efficacy and safety compared with mycophenolate mofetil in patients who have moderate to severe active forms of the disorder and who require up to 120 mg of oral prednisone or its equivalent daily.

Full Story:
eMPR.com
More Summaries:
pemphigus vulgaris, Rituximab
3/27/2017

EIA data show that ethanol production in the US averaged over 1 million barrels per day for the 21st straight week, and the four-week average rose to an annualized rate of 15.9 billion gallons.

Full Story:
BiofuelsDigest.com
3/27/2017

Xenon Pharmaceuticals said it failed to hit the primary endpoint of a midstage study of its candidate XEN801, which was assessed as a treatment for moderate to severe acne. The drug did not show noticeable differences in lesion count when compared with a vehicle gel after 12 weeks of use, and the company said the study's results do not support continued development of the treatment.

Full Story:
BioCentury
More Summaries:
Xenon Pharmaceuticals
3/27/2017

The European Medicines Agency has accepted for review Sun Pharmaceutical Industries' and Almirall's marketing authorization application for MK-3222, or tildrakizumab, the companies' monoclonal antibody against IL-23 as a treatment for moderate to severe plaque psoriasis.

Full Story:
BioCentury
3/27/2017

Pfizer's meningococcal group B vaccine Trumenba has been recommended by the European Medicines Agency's Committee for Medicinal Products for Human Use as a preventive vaccine against invasive meningococcal disease caused by Neisseria meningitidis serogroup B in patients ages 10 years and above.

3/27/2017

OK Food is recalling various varieties of its fully cooked breaded chicken products after five consumers reported finding metal pieces in the items, and Food Safety and Inspection Service investigators found metal pieces during verification. The recalled items bear the establishment number P-7092, were produced from Dec. 19, 2016, to March 7, 2017, and were distributed nationwide to retail institutions and locations.